Event Participants
Executives
3 Niren Kaul, Ritu Mittal, Somnath Chatterjee
Analysts
11 Aditya Khandelwal, Ankur Kumar, Bhavya Sanghavi, Hitaindra Pradhan, Mohammed Patel, Nilay Parekh, Om Sanghavi, Rajat Baldewa, Rajeev Jain, Riddhi Vora, Siddhant Kanodia
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Income | ₹88.7 crores | +21% YoY (₹73.5 crores in Q1 FY26); driven by mature center growth (12.3% YoY), new center ramp-up, and genomics revenue (+136% YoY) |
| Patients Served | 0.38 million | +12.4% QoQ; repeat rate ~40% (absolute repeat volumes not declining, diluted by new patient additions) |
| Tests Performed | 2.10 million | ~10-11% YoY; test/patient at 5.56; revenue per test rose on mix shift (no price increases) |
| Revenue per Patient | ₹2,321 | Blend of full-price B2C walk-ins and B2B; CTHS rate correction (mid-Oct 2025) added ~1.5% top-line benefit |
| EBITDA | ₹31.5 crores | +28% YoY (₹24.7 crores); EBITDA per patient ₹835 |
| EBITDA Margin | 36% | +200 bps YoY (34%); operating leverage, Roche biochemistry deal (lower COGS), and genomics mix contributing |
| PAT | ₹12.8 crores | +40% YoY (₹9.2 crores); PAT margin 14.7% |
| Mature Centers EBITDA Margin | 40.9% | Centers >2 years old; deemed sustainable as fixed costs spread over larger base |
| Sub-2-Year Centers EBITDA Margin | 6.5% | Turned positive from -5.5% in Q4 FY26; expected to continue improving, though new additions may dilute |
| Genomics Revenue | ₹1.37 crores | +136% YoY; 5 consecutive quarters of sequential growth; 80% B2C / 20% B2B |
| Network | 72 centers | 45 mature + 27 <2 years; added 1 hub + 3 spokes in Q1, 2 hubs + 3 spokes in Jul-Aug; 214 franchisee collection centers |
Geographic & Segment Commentary
West Bengal (Core Market): Greater Kolkata operates 9 hubs (5 in proper Kolkata plus 6 spokes); management sees scope for another 3 hubs and 6 spokes in Kolkata district and believes Greater Kolkata hub count can double. Several West Bengal districts remain uncovered and are targeted for expansion, with a concentric hub → spoke → collection center strategy.
Jharkhand (New Geography): First hub commissioned during the quarter; a second hub is planned for FY27, to be filled with at least 5 spokes. Marks the initial step in building a broader regional presence beyond West Bengal.
Northeast (Assam & Tripura): Assam already has one hub with one spoke commissioned and another spoke under development; a hub in Agartala, Tripura will follow shortly.
Genomics / Advanced Diagnostics: Revenue of ₹1.37 crores (+136% YoY) in Q1; only genomics lab based in Eastern India. GeneXus equipment (unique in the region) is in final validation, reducing oncology sequencing turnaround from 14-17 days to 48 hours. Capabilities span prenatal diagnostics, inherited diseases, pharmacogenomics, and oncology molecular panels.
Company-Specific & Strategic Commentary
Technology & AI Leadership: Launched a blood test for Alzheimer's disease with positive doctor feedback; initiated an AI-based early-detection project for Alzheimer's from plain brain MRI with a team of neurologists and neuroradiologists, supported by CSIR.
Margin & Cost Initiatives: Switched main biochemistry platform from Siemens to Roche with a better commercial deal, reducing cost of goods sold. Centralized procurement and existing infrastructure continue to underpin operating leverage as the network scales.
Hub-and-Spoke Network Model: Concentric expansion approach—hubs anchor clusters, spokes build density, and collection centers (214, all franchisee) extend reach. Spoke conversion follows when collection-center volumes justify radiology capability (ultrasound, X-ray, echo). Franchisees are shifted to further locations when spokes are added.
Genomics as a Differentiated Pillar: ₹22 crores invested over three years; lab staffed with 6-7 PhD scientists and a bioinformatics team. No major incremental capex expected for the next 2-3 years, leveraging existing infrastructure. Management positions this as a key growth pillar for the region.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| EBITDA Margin | ≥34% for FY27 | Q2 strong (disease/rainy season), Q3 muted (festivities/winter), Q4 strong; management expects volume-driven operating leverage to hold margins above 34% |
| Network Size | 100 centers by FY28 | On track; FY27 plan is 4 hubs + 7 spokes (3 hubs + 6 spokes already commissioned in Apr-Aug 2026) |
| Capex | ₹70-80 crores for FY27 | Hub: ₹10-10.5 crores each; spoke: ₹1.5-2 crores each |
| Genomics Growth | ~20% QoQ growth in FY27 | Strong adoption among medical fraternity; education and awareness building across Eastern India expected to sustain growth |
| Longer-Term EBITDA Margin | >33-34% by FY28-29 | Mature centers at 40.9% EBITDA and sub-2-year centers turning positive support progressive margin expansion |
Risks & Constraints
| Risk | Context |
|---|---|
| New Center Dilution | 27 of 72 centers are under 2 years old (some only 3-6 months), keeping ROE/ROCE below peers. Sub-2-year centers are at just 6.5% EBITDA; full-year margin guidance assumes these ramp smoothly. |
| Cannibalization | Spoke and collection-center conversions can divert volumes from nearby mature centers; management acknowledges "a bit of cannibalization" but maintains overall business grows and reach widens. |
| New Geography Ramp-Up | Entry into Jharkhand, Tripura, and Assam brings regulatory, doctor-connect, and brand-building challenges; organized diagnostics penetration in the East is still low, requiring education of the medical fraternity. |
| Seasonality | Q3 (Oct-Dec) is structurally muted due to festivities and winter, creating variability that could pressure full-year EBITDA if the quarter is weaker than expected. |
| B2B / B2B Mix Pressures | B2B segment carries structurally lower margins; genomics mix is shifting toward B2B (currently 80/20 B2C/B2B). Management relies on volume growth to compensate for lower realizations. |
| Genomics Scale-Up | At ₹1.37 crores per quarter, genomics is small; segment margins of 15-20% could drag blended margins near-term until volumes build. |
Q&A Highlights
Margin Expansion & FY27 Profitability Outlook
- Question: What drove the margin expansion of ~400 bps, and are the 33-34% margins sustainable by FY29? (Om Sanghavi, PhillipCapital)
- Answer: Margin expansion is volume-led—"as revenues scale up and major fixed costs remain the same, there is operating leverage." Mature centers grew revenue 12.5% QoQ, and sub-2-year centers turned positive. Management expects to exceed 33-34% by FY28-29 and guides EBITDA of "minimum 34%" for FY27, with Q2 strong, Q3 muted, and Q4 strong seasonality. (Ritu Mittal)
- Question: Is the 40.9% mature-center margin sustainable? (Ankur Kumar, Alpha Capital)
- Answer: Yes—beyond volume growth, genomics contributions and the Roche biochemistry deal (better COGS) support margins. (Ritu Mittal)
Genomics Growth Strategy
- Question: What is the demand outlook for genomics over 3-4 years? (Rajat Baldewa, Kizuna Wealth)
- Answer: Oncology treatment is getting personalized, so most oncology specimens will require genomic study. Suraksha has acquired GeneXus—the only unit in Eastern India—in final validation, cutting turnaround from 14-17 days to 48 hours. The lab is the only genomics lab based out of East India, with 6-7 PhD scientists and bioinformatics support. (Somnath Chatterjee; Niren Kaul)
- Question: What is the India genomics market size, and what revenue can current capex support? (Siddhant Kanodia, Tusk Investments)
- Answer: India genomics market is expected to reach ~₹450 million by 2030 (global data reference). Mature pure-genomics labs in India generate ₹100-250 crores in turnover. Suraksha's lab is fully equipped for all prevalent global technologies; no major incremental capex for 2-3 years. (Somnath Chatterjee; Niren Kaul)
Network Expansion & Capex
- Question: Is the 100-center target by FY28 on track, and what is the capex outlook? (Om Sanghavi, PhillipCapital)
- Answer: Yes, on track for 100 centers by FY28. FY27 capex will be around ₹70-80 crores. (Ritu Mittal)
- Question: What are capex requirements for hub vs spoke, and how long to breakeven? (Rajeev Jain, Arcane Wealth)
- Answer: Hub costs ₹10-10.5 crores; spoke ₹1.5-2 crores. Center-level breakeven: spoke 3-4 months, hub 8-9 months. (Ritu Mittal)
Center-Level Economics
- Question: What was the revenue split between mature and sub-2-year centers, and their margins? (Rajat Baldewa, Kizuna Wealth)
- Answer: Total sales of ₹88 crores; sub-2-year centers contributed ~₹8.5 crores, rest from mature centers. Sub-2-year centers turned positive at 6.5% EBITDA from -5.5% last quarter. Mature centers grew 12.3% YoY. (Ritu Mittal)
- Question: Will new centers dilute margins in FY28 given 50-50 new-territory mix? (Bhavya Sanghavi, PhillipCapital)
- Answer: No—management expects margins to increase despite the new geography mix, driven by mature center scale and steady ramp of newer centers. (Ritu Mittal)
Kolkata Market Opportunity
- Question: What is Suraksha's market share and expansion headroom in Kolkata? (Aditya Khandelwal, Securities Investment Management)
- Answer: Organized players are less penetrated in the East (mostly mom-and-pop labs); Suraksha is the largest organized player in the region. Greater Kolkata spans parts of North 24 Parganas, Howrah, and Hooghly (population ~2 crores). Proper Kolkata has 5 hubs and 6 spokes today; potential for 3 more hubs and 6 spokes. Greater Kolkata currently has 9 hubs and can be doubled, with future locations driven by market demand. (Ritu Mittal; Niren Kaul)
Revenue Guidance & Conservative Stance
- Question: Why does Suraksha guide only ~15% revenue growth when larger peers guide higher? (Mohammed Patel, Edelweiss)
- Answer: "We have been a bit conservative over it. We are just coming to terms at our pace... the results would speak for themselves." No dearth of effort, company guided conservatively despite strong current momentum. (Niren Kaul)
B2B/B2C Mix & Realizations
- Question: How is Suraksha balancing B2B volume growth with healthy realizations? (Rajeev Jain, Arcane Wealth)
- Answer: B2C does not face margin challenges—"we have patients walking into our centers paying full price." B2B carries margin pressure, but volume compensates; management avoids deep discounting in collection centers. (Ritu Mittal)
Cannibalization Risk
- Question: As hubs/spokes densify, could there be cannibalization of mature centers? (Hitaindra Pradhan, Maximal Capital)
- Answer: "There is always a bit of cannibalization when we set up spoke centers, but overall business does not take a beating and it caters to a wider area; patient reach becomes more." No observed downtrend. (Ritu Mittal)
Repeat Rate Dilution
- Question: Why has the repeat rate fallen from 52% (FY22-23) to ~40%? (Rajat Baldewa, Kizuna Wealth)
- Answer: As reach expands, new patient numbers increase, making repeat patients appear smaller as a share—absolute repeat volumes are not declining. (Ritu Mittal)
Policy Benefit (CTHS)
- Question: Did CTHS benefit flow through in Q1, given strong realizations? (Bhavya Sanghavi, PhillipCapital)
- Answer: Yes—CTHS rate increase from mid-October 2025 gave an incremental benefit, with public sector corporate contribution around 15% of revenue; top-line benefit estimated at ~1.5%. (Niren Kaul)
Key Takeaway
Suraksha Diagnostic Ltd delivered a strong Q1 FY27 with total income of ₹88.7 crores (+21% YoY), EBITDA up 28% to ₹31.5 crores at a 36% margin (+200 bps YoY), and PAT of ₹12.8 crores (+40% YoY). Mature centers held 40.9% EBITDA margins while sub-2-year centers turned profitable at 6.5% (from -5.5% in Q4 FY26), aided by operating leverage, the Roche biochemistry agreement, and the CTHS rate increase. Genomics revenue grew 136% YoY to ₹1.37 crores, supported by the GeneXus platform (48-hour sequencing) and the only East-India-based genomics lab. Management guides to a minimum 34% EBITDA margin for FY27, 100 centers by FY28, and ₹70-80 crores capex, with hub-and-spoke expansion into Jharkhand, Tripura, and Assam underway. Watch points include new-center dilution of ROE, potential spoke cannibalization, and the early-stage scale of the genomics business.